KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Deferred Taxes (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 13 years of Deferred Taxes data on record, last reported at $232.5 million in Q4 2025.

  • For Q4 2025, Deferred Taxes fell 17.02% year-over-year to $232.5 million; the TTM value through Dec 2025 reached $785.4 million, up 3.71%, while the annual FY2025 figure was $785.4 million, 3.71% up from the prior year.
  • Deferred Taxes reached $232.5 million in Q4 2025 per REGN's latest filing, down from $278.6 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $286.3 million in Q4 2023 and bottomed at -$10.1 million in Q1 2021.
  • Average Deferred Taxes over 5 years is $183.3 million, with a median of $190.4 million recorded in 2024.
  • Peak YoY movement for Deferred Taxes: surged 2327.72% in 2022, then crashed 43.57% in 2024.
  • A 5-year view of Deferred Taxes shows it stood at -$10.1 million in 2021, then skyrocketed by 2869.31% to $279.7 million in 2022, then rose by 2.36% to $286.3 million in 2023, then dropped by 2.13% to $280.2 million in 2024, then decreased by 17.02% to $232.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $232.5 million in Q4 2025, $278.6 million in Q3 2025, and $135.2 million in Q2 2025.